#METABOLOMICS WORKBENCH lai_yunjia_20210422_095402 DATATRACK_ID:2597 STUDY_ID:ST001748 ANALYSIS_ID:AN002847 PROJECT_ID:PR001120
VERSION             	1
CREATED_ON             	April 23, 2021, 9:08 am
#PROJECT
PR:PROJECT_TITLE                 	Rationally designed bacterial consortia to treat chronic immune-mediated colitis
PR:PROJECT_TITLE                 	and restore intestinal homeostasis
PR:PROJECT_TYPE                  	targeted metabolomics
PR:PROJECT_SUMMARY               	Environmental factors, mucosal permeability and defective immunoregulation drive
PR:PROJECT_SUMMARY               	overactive immunity to a subset of resident intestinal bacteria that mediate
PR:PROJECT_SUMMARY               	multiple inflammatory conditions. GUT-103 and GUT-108, live biotherapeutic
PR:PROJECT_SUMMARY               	products rationally designed to complement missing or underrepresented functions
PR:PROJECT_SUMMARY               	in the dysbiotic microbiome of IBD patients, address upstream targets, rather
PR:PROJECT_SUMMARY               	than targeting a single cytokine to block downstream inflammation responses.
PR:PROJECT_SUMMARY               	GUT-103, composed of 17 strains that synergistically provide protective and
PR:PROJECT_SUMMARY               	sustained engraftment in the IBD inflammatory environment, prevented, and
PR:PROJECT_SUMMARY               	treated chronic immune-mediated colitis. Therapeutic application of GUT-108
PR:PROJECT_SUMMARY               	reversed established colitis in a humanized chronic T cell-mediated mouse model.
PR:PROJECT_SUMMARY               	It decreased pathobionts while expanding resident protective bacteria; produced
PR:PROJECT_SUMMARY               	metabolites promoting mucosal healing and immunoregulatory responses; decreased
PR:PROJECT_SUMMARY               	inflammatory cytokines and Th-1 and Th-17 cells; and induced
PR:PROJECT_SUMMARY               	interleukin-10-producing colonic regulatory cells, and IL-10-independent
PR:PROJECT_SUMMARY               	homeostatic pathways. We propose GUT-108 for treating and preventing relapse for
PR:PROJECT_SUMMARY               	IBD and other inflammatory conditions characterized by unbalanced microbiota and
PR:PROJECT_SUMMARY               	mucosal permeability.
PR:INSTITUTE                     	University of North Carolina at Chapel Hill
PR:DEPARTMENT                    	UNC Departments of Medicine, Microbiology and Immunology, Center for
PR:DEPARTMENT                    	Gastrointestinal Biology and Disease; UNC Department of Environmental Sciences
PR:DEPARTMENT                    	and Engineering
PR:LABORATORY                    	R. Balfour Sartor Lab; Kun Lu Lab
PR:LAST_NAME                     	Lai
PR:FIRST_NAME                    	Yunjia
PR:ADDRESS                       	1104 MHRC, 135 Dauer Drive, NC
PR:EMAIL                         	lai7@live.unc.edu
PR:PHONE                         	919-480-5489
PR:FUNDING_SOURCE                	Gusto Global LLC.; National Institute of Health (NIH) (grant no. P40OD010995;
PR:FUNDING_SOURCE                	P30DK034987; P01DK094779); the Crohn’s and Colitis Foundation
PR:PUBLICATIONS                  	Nature Communications
#STUDY
ST:STUDY_TITLE                   	Rationally designed bacterial consortia to treat chronic immune-mediated colitis
ST:STUDY_TITLE                   	and restore intestinal homeostasis
ST:STUDY_TYPE                    	Targeted metabolomics
ST:STUDY_SUMMARY                 	GUT103 and GUT108, live biotherapeutic products rationally designed to
ST:STUDY_SUMMARY                 	complement missing or underrepresented functions in the dysbiotic microbiome of
ST:STUDY_SUMMARY                 	IBD patients; they address upstream targets, rather than targeting a single
ST:STUDY_SUMMARY                 	cytokine to block downstream inflammation responses. Systematic colonization
ST:STUDY_SUMMARY                 	experiments in colitis mouse models were performed to test their therapeutic
ST:STUDY_SUMMARY                 	effects. Targeted fecal metabolomics data uploaded here of bile acids,
ST:STUDY_SUMMARY                 	short-chain fatty acids, and tryptophan metabolites provides a unique metabolome
ST:STUDY_SUMMARY                 	perspective for evaluation of the therapeutic potential of GUT103 and GUT108.
ST:INSTITUTE                     	University of North Carolina at Chapel Hill
ST:LABORATORY                    	Gusto Global LLC.
ST:LAST_NAME                     	Lai
ST:FIRST_NAME                    	Yunjia
ST:ADDRESS                       	1104 MHRC, 135 Dauer Drive, Chapel Hill, NC 27599, USA
ST:EMAIL                         	lai7@live.unc.edu
ST:PHONE                         	+1 919-480-5489
ST:NUM_GROUPS                    	12
ST:PUBLICATIONS                  	Nature Communications
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
SU:GENOTYPE_STRAIN               	GF 129SvEv background IL-10-deficient mice (Il10-/-); Il10-eGFP-reporter
SU:GENOTYPE_STRAIN               	(Il10+/eGFP) mice (on a C57BL/6J background)
SU:AGE_OR_AGE_RANGE              	8-12 week old
SU:ANIMAL_ANIMAL_SUPPLIER        	8-12 week-age GF 129SvEv background IL-10-deficient mice (Il10-/-) were obtained
SU:ANIMAL_ANIMAL_SUPPLIER        	from University of North Carolina National Gnotobiotic Rodent Resource Center;
SU:ANIMAL_ANIMAL_SUPPLIER        	Il10-eGFP-reporter (Il10+/eGFP) mice on a C57BL/6J background mice were
SU:ANIMAL_ANIMAL_SUPPLIER        	originally provided by Dr. C. L. Karp (Global Health, Bill & Melinda Gates
SU:ANIMAL_ANIMAL_SUPPLIER        	Foundation, USA)
SU:ANIMAL_HOUSING                	Germ-free and gnotobiotic conditions at National Gnotobiotic Rodent Resource
SU:ANIMAL_HOUSING                	Center, University of North Carolina
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_1_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_1_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_2_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_2_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_3_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_3_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_4_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_4_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_5_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_5_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_6_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_6_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_7_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_7_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_8_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_8_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_9_EER	Treatment:EER bacterial strains	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_9_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_10_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_10_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_11_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_11_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_12_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_12_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_13_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_13_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_14_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_14_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_15_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_15_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_16_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_16_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_17_Therapy	Treatment:EER plus GUT-103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_17_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_18_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_18_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_19_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_19_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_20_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_20_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_21_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_21_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_22_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_22_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_23_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_23_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_24_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_24_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_25_Prevention	Treatment:GUT-103 plus EER	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_25_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_26_GUT103	Treatment:GUT103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_26_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_27_GUT103	Treatment:GUT103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_27_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_28_GUT103	Treatment:GUT103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_28_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_29_GUT103	Treatment:GUT103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_29_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	bileacid_Exp1_30_GUT103	Treatment:GUT103	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp1_30_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_1_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_1_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_2_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_2_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_3_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_3_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_4_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_4_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_5_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_5_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_6_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_6_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_7_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_7_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_8_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_8_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_9_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_9_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_10_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_10_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_11_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_11_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_12_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_12_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_13_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_13_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_14_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_14_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_15_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_15_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_16_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_16_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_17_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_17_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_18_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_18_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_19_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_19_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_20_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_20_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_21_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_21_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_22_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_22_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_1_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_1_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_2_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_2_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_3_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_3_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_4_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_4_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_5_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_5_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_6_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_6_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_7_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_7_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_8_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_8_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_9_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_9_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_10_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_10_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_11_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_11_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_12_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_12_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_13_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_13_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_14_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_14_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_15_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_15_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_16_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_16_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_17_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_17_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_18_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_18_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_19_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_19_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_20_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_20_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_21_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_21_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp2_22_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp2_22_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_1_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_1_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_3_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_3_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_4_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_4_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_5_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_5_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_6_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_6_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_14_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_14_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_15_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_15_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_17_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_17_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_18_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_18_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_19_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_19_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_20_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_20_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_1_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_1_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_3_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_3_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_4_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_4_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_5_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_5_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_6_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_6_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_14_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_14_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_15_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_15_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_17_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_17_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_18_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_18_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_19_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_19_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	bileacid_Exp3_20_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=bile acids; RAW_FILE_NAME=bileacid_Exp3_20_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_1_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_1_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_2_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_2_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_4_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_4_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_5_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_5_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_6_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_6_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_7_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_7_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_8_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_8_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_9_EER	Treatment:EER bacterial strains	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_9_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_10_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_10_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_11_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_11_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_12_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_12_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_13_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_13_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_14_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_14_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_15_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_15_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_16_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_16_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_17_Therapy	Treatment:EER plus GUT-103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_17_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_18_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_18_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_19_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_19_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_20_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_20_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_21_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_21_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_22_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_22_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_23_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_23_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_24_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_24_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_25_Prevention	Treatment:GUT-103 plus EER	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_25_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_26_GUT103	Treatment:GUT103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_26_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_27_GUT103	Treatment:GUT103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_27_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_28_GUT103	Treatment:GUT103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_28_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_29_GUT103	Treatment:GUT103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_29_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	scfa_Exp1_30_GUT103	Treatment:GUT103	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp1_30_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_1_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_1_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_2_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_2_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_3_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_3_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_4_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_4_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_5_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_5_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_6_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_6_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_7_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_7_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_8_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_8_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_9_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_9_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_10_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_10_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_11_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_11_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_12_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_12_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_13_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_13_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_14_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_14_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_15_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_15_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_16_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_16_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_17_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_17_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_18_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_18_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_19_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_19_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_20_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_20_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_21_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_21_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_22_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_22_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_1_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_1_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_2_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_2_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_3_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_3_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_4_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_4_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_5_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_5_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_6_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_6_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_7_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_7_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_8_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_8_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_9_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_9_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_10_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_10_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_11_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_11_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_12_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_12_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_13_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_13_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_14_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_14_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_15_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_15_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_16_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_16_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_17_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_17_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_18_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_18_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_19_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_19_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_20_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_20_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_21_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_21_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp2_22_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp2_22_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_1_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_1_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_3_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_3_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_4_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_4_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_5_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_5_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_6_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_6_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_14_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_14_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_15_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_15_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_17_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_17_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_18_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_18_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_19_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_19_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_20_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_20_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_1_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_1_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_3_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_3_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_4_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_4_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_5_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_5_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_6_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_6_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_14_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_14_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_15_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_15_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_17_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_17_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_18_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_18_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_19_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_19_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	scfa_Exp3_20_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=SCFAs; RAW_FILE_NAME=scfa_Exp3_20_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_1_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_1_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_2_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_2_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_3_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_3_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_4_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_4_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_5_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_5_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_6_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_6_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_7_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_7_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_8_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_8_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_9_EER	Treatment:EER bacterial strains	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_9_EER
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_10_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_10_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_11_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_11_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_12_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_12_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_13_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_13_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_14_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_14_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_15_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_15_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_16_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_16_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_17_Therapy	Treatment:EER plus GUT-103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_17_Therapy
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_18_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_18_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_19_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_19_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_20_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_20_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_21_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_21_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_22_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_22_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_23_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_23_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_24_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_24_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_25_Prevention	Treatment:GUT-103 plus EER	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_25_Prevention
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_26_GUT103	Treatment:GUT103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_26_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_27_GUT103	Treatment:GUT103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_27_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_28_GUT103	Treatment:GUT103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_28_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_29_GUT103	Treatment:GUT103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_29_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10+/eGFP	trps_Exp1_30_GUT103	Treatment:GUT103	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp1_30_GUT103
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_1_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_1_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_2_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_2_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_3_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_3_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_4_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_4_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_5_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_5_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_6_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_6_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_7_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_7_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_8_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_8_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_9_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_9_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_10_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_10_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_11_Hu+PBS_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_11_Hu+PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_12_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_12_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_13_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_13_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_14_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_14_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_15_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_15_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_16_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_16_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_17_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_17_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_18_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_18_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_19_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_19_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_20_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_20_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_21_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_21_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_22_Hu+GUT108_week2	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_22_Hu+GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_1_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_1_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_2_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_2_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_3_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_3_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_4_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_4_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_5_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_5_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_6_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_6_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_7_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_7_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_8_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_8_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_9_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_9_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_10_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_10_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_11_Hu+PBS_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_11_Hu+PBS_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_12_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_12_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_13_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_13_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_14_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_14_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_15_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_15_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_16_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_16_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_17_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_17_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_18_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_18_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_19_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_19_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_20_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_20_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_21_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_21_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp2_22_Hu+GUT108_week4	Treatment:After 2 wk GUT/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp2_22_Hu+GUT108_week4
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_1_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_1_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_3_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_3_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_4_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_4_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_5_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_5_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_6_PBS_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_6_PBS_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_14_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_14_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_15_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_15_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_17_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_17_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_18_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_18_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_19_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_19_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_20_GUT108_week0	Treatment:Before GUT108/PBS therapy (baseline)	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_20_GUT108_week0
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_1_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_1_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_3_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_3_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_4_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_4_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_5_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_5_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_6_PBS_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_6_PBS_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_14_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_14_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_15_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_15_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_17_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_17_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_18_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_18_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_19_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_19_GUT108_week2
SUBJECT_SAMPLE_FACTORS           	Il10-/-	trps_Exp3_20_GUT108_week2	Treatment:After GUT108/PBS therapy	Target of analysis=tryptophan metabolites; RAW_FILE_NAME=trps_Exp3_20_GUT108_week2
#COLLECTION
CO:COLLECTION_SUMMARY            	For samples for targeted metabolomics analysis, mouse cecal content and/or feces
CO:COLLECTION_SUMMARY            	were collected.
CO:COLLECTION_PROTOCOL_ID        	University of North Carolina at Chapel Hill Institutional Animal Care and Use
CO:COLLECTION_PROTOCOL_ID        	Committee (18-266.0-B)
CO:SAMPLE_TYPE                   	Feces
CO:STORAGE_CONDITIONS            	-80℃
#TREATMENT
TR:TREATMENT_SUMMARY             	For treatment 200 µl of diluted human donor stool was applied by oral gavage on
TR:TREATMENT_SUMMARY             	day 1 to Il10-/- mice. The stool was derived from a single healthy donor,
TR:TREATMENT_SUMMARY             	Donor-Y, and was previously found to induce moderate to severe colitis in
TR:TREATMENT_SUMMARY             	Il10-/- mice. One gram stool was diluted 100- fold with anaerobic PBS, and
TR:TREATMENT_SUMMARY             	vigorously mixed for 5 minutes under anaerobic conditions. For application of
TR:TREATMENT_SUMMARY             	GUT-103 and GUT-108, 300µl resuspended strain mixture in anaerobic PBS was
TR:TREATMENT_SUMMARY             	applied per mouse by oral gavage. GUT-103 and GUT-108 strains were grown
TR:TREATMENT_SUMMARY             	individually, subsequently mixed to equal concentrations (cfu/ml), and provided
TR:TREATMENT_SUMMARY             	at a dose of 2.0x10+7 cfu/strain in a total volume of 300 µl. The strain
TR:TREATMENT_SUMMARY             	mixture was provided four times via oral gavage on days 15, 17, 22 and 25
TR:TREATMENT_SUMMARY             	(Il10-/- mice) or on days 1, 3, 8 and 11 (Il10+/eGFP mice).
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Bile acids, SCFAs, and tryptophan metabolites were extracted (with careful
SP:SAMPLEPREP_SUMMARY            	cleanup or derivatization procedures whenever necessary) and analyzed using mass
SP:SAMPLEPREP_SUMMARY            	spectrometry-based platforms.
SP:SAMPLEPREP_PROTOCOL_FILENAME  	Protocols.pdf
SP:PROCESSING_STORAGE_CONDITIONS 	On ice
SP:EXTRACTION_METHOD             	Bile acid: SPE and LLE; SCFA: alkaline aqueous extraction; tryptophan
SP:EXTRACTION_METHOD             	metabolites: 1:1 MeOH:Water LLE
SP:EXTRACT_CLEANUP               	For Bile acids, C18 solid-phase extraction cleanup and concentration was used.
SP:EXTRACT_STORAGE               	-80℃
SP:SAMPLE_DERIVATIZATION         	For SCFAs, propyl chloroformate derivatization was performed.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	C18 LC (BEH C18) and (HSS T3) for quantitation of bile acids
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Thermo Vanquish
CH:COLUMN_NAME                   	Waters Acquity BEH C18 (150 x 2mm, 1.7um)
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Quantis QQQ
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Optimized SRM method scanning characteristic MS2 fragment ion for absolute
MS:MS_COMMENTS                   	quantitation.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	ng/g
MS_METABOLITE_DATA_START
Samples	bileacid_Exp1_1_EER	bileacid_Exp1_2_EER	bileacid_Exp1_3_EER	bileacid_Exp1_4_EER	bileacid_Exp1_5_EER	bileacid_Exp1_6_EER	bileacid_Exp1_7_EER	bileacid_Exp1_8_EER	bileacid_Exp1_9_EER	bileacid_Exp1_10_Therapy	bileacid_Exp1_11_Therapy	bileacid_Exp1_12_Therapy	bileacid_Exp1_13_Therapy	bileacid_Exp1_14_Therapy	bileacid_Exp1_15_Therapy	bileacid_Exp1_16_Therapy	bileacid_Exp1_17_Therapy	bileacid_Exp1_18_Prevention	bileacid_Exp1_19_Prevention	bileacid_Exp1_20_Prevention	bileacid_Exp1_21_Prevention	bileacid_Exp1_22_Prevention	bileacid_Exp1_23_Prevention	bileacid_Exp1_24_Prevention	bileacid_Exp1_25_Prevention	bileacid_Exp1_26_GUT103	bileacid_Exp1_27_GUT103	bileacid_Exp1_28_GUT103	bileacid_Exp1_29_GUT103	bileacid_Exp1_30_GUT103	bileacid_Exp2_1_Hu+PBS_week2	bileacid_Exp2_2_Hu+PBS_week2	bileacid_Exp2_3_Hu+PBS_week2	bileacid_Exp2_4_Hu+PBS_week2	bileacid_Exp2_5_Hu+PBS_week2	bileacid_Exp2_6_Hu+PBS_week2	bileacid_Exp2_7_Hu+PBS_week2	bileacid_Exp2_8_Hu+PBS_week2	bileacid_Exp2_9_Hu+PBS_week2	bileacid_Exp2_10_Hu+PBS_week2	bileacid_Exp2_11_Hu+PBS_week2	bileacid_Exp2_12_Hu+GUT108_week2	bileacid_Exp2_13_Hu+GUT108_week2	bileacid_Exp2_14_Hu+GUT108_week2	bileacid_Exp2_15_Hu+GUT108_week2	bileacid_Exp2_16_Hu+GUT108_week2	bileacid_Exp2_17_Hu+GUT108_week2	bileacid_Exp2_18_Hu+GUT108_week2	bileacid_Exp2_19_Hu+GUT108_week2	bileacid_Exp2_20_Hu+GUT108_week2	bileacid_Exp2_21_Hu+GUT108_week2	bileacid_Exp2_22_Hu+GUT108_week2	bileacid_Exp2_1_Hu+PBS_week4	bileacid_Exp2_2_Hu+PBS_week4	bileacid_Exp2_3_Hu+PBS_week4	bileacid_Exp2_4_Hu+PBS_week4	bileacid_Exp2_5_Hu+PBS_week4	bileacid_Exp2_6_Hu+PBS_week4	bileacid_Exp2_7_Hu+PBS_week4	bileacid_Exp2_8_Hu+PBS_week4	bileacid_Exp2_9_Hu+PBS_week4	bileacid_Exp2_10_Hu+PBS_week4	bileacid_Exp2_11_Hu+PBS_week4	bileacid_Exp2_12_Hu+GUT108_week4	bileacid_Exp2_13_Hu+GUT108_week4	bileacid_Exp2_14_Hu+GUT108_week4	bileacid_Exp2_15_Hu+GUT108_week4	bileacid_Exp2_16_Hu+GUT108_week4	bileacid_Exp2_17_Hu+GUT108_week4	bileacid_Exp2_18_Hu+GUT108_week4	bileacid_Exp2_19_Hu+GUT108_week4	bileacid_Exp2_20_Hu+GUT108_week4	bileacid_Exp2_21_Hu+GUT108_week4	bileacid_Exp2_22_Hu+GUT108_week4
Factors	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER bacterial strains	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:EER plus GUT-103	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT-103 plus EER	Treatment:GUT103	Treatment:GUT103	Treatment:GUT103	Treatment:GUT103	Treatment:GUT103	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:Before GUT108/PBS therapy (baseline)	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy	Treatment:After 2 wk GUT/PBS therapy
α-Muricholate	11.19	12.87	16.63	21.51	24.23	30.14	32.39	44.38	48.05	1151.67	1179.31	1327.85	1351.37	1364.01	3030.23	3599.01	5696.62	765.6	954.2	1026.58	1063.96	1087.52	1331.13	1384.41		611.7	1331.56	1382.54	2712.7	2840.91																																												
β-Muricholate	143.16	186.57	228.41	300.75	433.06	504.51	572.8	600.76	711.07	21248.93	21730.57	22058.5	23876.62	26698.31	33831.56	39948.9	52330.96	12629.71	14511.23	16633.13	17469.43	20152.17	21481.76	24101.83		14423.1	24116.84	30952.8	41582.39	43654.28																																												
Cholate	226.39	336.45	363.73	423.5	782.96	949.8	1053.65	1171.4	1561.06	1188.06	1260.67	1494.23	1642.78	1890.95	3787.25	4301.72		1688.84	1773.7	2070.24	2456.72	2525.52	2889.57	3546.57		1772.28	2912.23	4213.43	4240.56	4370.41																																												
Chenodeoxycholate	5.86	6.61	7.99	11.32	15.65	22.03	23.11	37.1	38.17	145.28	172.95	183.69	212.43	220.6	393.37	452.7	584.26	241.65	254.13	278.7	324.78	356.11	371.77	388.44		149.56	166.16	206.74	466.14	485.67																																												
Lithocholate	53.43	74.76	97.12	100.9	106.66	127.92	131.51	219.67	242.37	141.6	147.73	174.2	184.04	192.02	206.18	273.79	343.14	220.31	253.94	265.9	268.86	326.39	338.78	422.93		158.11	205	225.49	350.64	376.56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.42	0	0	0	0	0	0	0	0	0	0	2.644	0	21.386	1.002	5.623	0	11.086	9.764	5.081	0.084	8.109	11.093	14.072
Ursodeoxycholate	4.35	6.28	8.23	14.33	18.21	24.55	24.6	26.82	27.42	253.09	334.54	397.1	418.62	502.5	705.98	810.97	836.86	208.67	250.65	282.79	327.67	378.14	402.18	403.83		214.69	299.07	488.76	868.8	936.37																																												
Deoxycholate	3.95	4.03	4.08	4.8	8.2	8.63	9.75			0.84	2	2.03	2.64	3.59	4.61			2.15	5.98	6.06	8.18	11.24	42.78			3.05	6.44	3.93	5.3	2.83	0.461	0.222	0.282	0.353	0.117	0	0.043	0.082	0.206	0.056	0.076	0.262	0.271	0.328	0.42	0.207	0.099	0.063	0.058	0.044	0.547	0.256	0.372	0	0.075	0.149	0.194	0.047	0.108	0.068	0.134	101.013	7.052	346.348	28.848	133.854	31.253	569.657	437.305	360.985	7.515	128.193	490.691	561.32
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	retention time	quantified m/z	PubChem_CID	KEGG_ID
α-Muricholate	14	407.3	5283852	C17647
β-Muricholate	14	407.3	5283853	C17726
Cholate	14	407.3	221493	C00695
Chenodeoxycholate	14	391.3	10133	C02528
Lithocholate	14	375.3	9903	C03990
Ursodeoxycholate	14	391.3	31401	C07880
Deoxycholate	14	391.3	222528	C04483
METABOLITES_END
#END